DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

British Journal of Clinical Pharmacology

Volumn 80, Issue 3, 2015, Pages 581-588

  Falvella, Felicia Stefania ^a   Cheli, Stefania ^a   Martinetti, Antonia ^b   Mazzali, Cristina ^a,c   Iacovelli, Roberto ^b   Maggi, Claudia ^b   Gariboldi, Manuela ^b,d   Pierotti, Marco Alessandro ^b   Di Bartolomeo, Maria ^b   Sottotetti, Elisa ^b   Mennitto, Roberta ^b   Bossi, Ilaria ^b   De Braud, Filippo ^b   Clementi, Emilio ^a,e   Pietrantonio, Filippo ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c POLITECNICO DI MILANO   (Italy)

^d FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^e SCIENTIFIC INSTITUTE   (Italy)

Author keywords

colorectal cancer; fluoropyrimidines; irinotecan; pharmacogenetics; single nucleotide polymorphisms

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; GENOMIC DNA; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MICRORNA; MICRORNA 27A; OXALIPLATIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE; MIRN27 MICRORNA, HUMAN; PLATINUM COMPLEX; UGT1A1 ENZYME;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; DIARRHEA; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DNA EXTRACTION; DRUG SAFETY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REPEATED DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; DEFICIENCY; GENETICS; HETEROZYGOTE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LEUCOVORIN; MALE; MICRORNAS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES;

EID: 84940452418     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12631     Document Type: Article

References (29)

1. Grothey A, Sargent D, Goldberg RM, Schmoll HJ,. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-14.
2. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A,. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-37.
3. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M,. Masi G; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-6.
4. Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A,. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 23: 1609-18.
5. Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M,. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 2013; 94: 640-5.
6. Teh LK, Hamzah S, Hashim H, Bannur Z, Zakaria ZA, Hasbullani Z, Shia JK, Fijeraid H, Md Nor A, Zailani M, Ramasamy P, Ngow H, Sood S, Salleh MZ,. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients. Ther Drug Monit 2013; 35: 624-30.
7. van Kuilenburg AB, Meijer J, Mul AN, Meinsma R, Schmid V, Dobritzsch D, Hennekam RC, Mannens MM, Kiechle M, Etienne-Grimaldi MC, Klümpen HJ, Maring JG, Derleyn VA, Maartense E, Milano G, Vijzelaar R, Gross E,. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet 2010; 128: 529-38.
8. Gross E, Busse B, Riemenschneider M, Neubauer S, Seck K, Klein HG, Kiechle M, Lordick F, Meindl A,. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One 2008; 3: e4003.
9. Hirota T, Date Y, Nishibatake Y, Takane H, Fukuoka Y, Taniguchi Y, Burioka N, Shimizu E, Nakamura H, Otsubo K, Ieiri I,. Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues. Lung Cancer 2012; 77: 16-23.
10. Offer SM, Butterfield GL, Jerde CR, Fossum CC, Wegner NJ, Diasio RB,. microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol Cancer Ther 2014; 13: 742-51.
11. Barbarino JM, Haidar CE, Klein TE, Altman RB,. PharmGKB summary: very important pharmacogene information for UGT1A1. Pharmacogenet Genomics 2014; 24: 177-83.
12. Innocenti F, Schilsky RL, Ramírez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML, Salgia R, Ratain MJ,. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol 2014; 32: 2328-34.
13. Di Bartolomeo M, Ciarlo A, Bertolini A, Barni S, Verusio C, Aitini E, Pietrantonio F, Iacovelli R, Dotti KF, Maggi C, Perrone F, Bajetta E,. Capecitabine, oxaliplatin and irinotecan in combination with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An I.T.M.O. phase II study. Eur J Cancer 2015; 51: 473-81.
14. Pietrantonio F, Coppa J, De Braud F, Mazzaferro V, Biondani P, Perrone F, Dotti KF, Cotsoglou C, Di Bartolomeo M,. Phase I/II study of capecitabine, oxaliplatin, irinotecan and cetuximab (COI-E regimen) as perioperative treatment of high-risk or borderline resectable colorectal cancer liver metastases (CLM). Eur J Cancer 2013; vol. 49 (Suppl 2, abstr 2223).
15. Rodriguez S, Gaunt TR, Day IN,. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009; 169: 505-14.
16. Streiner DL, Norman GR,. Correction for multiple testing: is there a resolution? Chest 2011; 140: 16-18.
17. Gruenberger T, Bridgewater JA, Chau I, Alfonso PG, Rivoire M, Lasserre S, Waterkamp D, Adam R,. Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA. J Clin Oncol 2013; 31 (Suppl, abstr 3619)
18. Loupakis F, Cremolini C, Salvatore L, Masi G, Sensi E, Schirripa M, Michelucci A, Pfanner E, Brunetti I, Lupi C, Antoniotti C, Bergamo F, Lonardi S, Zagonel V, Simi P, Fontanini G, Falcone A,. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014; 50: 57-63.
19. Bajetta E, Celio L, Ferrario E, Di Bartolomeo M, Denaro A, Dotti K, Mancin M, Bajetta R, Colombo A, Pusceddu S,. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Ann Oncol 2007; 18: 1810-6.
20. Iacovelli R, Pietrantonio F, Palazzo A, Maggi C, Ricchini F, de Braud F, Di Bartolomeo M,. Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil. A meta-analysis of published trials. Br J Clin Pharmacol 2014; 78: 1228-37.
21. Oostendorp LJ, Stalmeier PF, Pasker-de Jong PC, Van der Graaf WT, Ottevanger PB,. Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer. Anticancer Drugs 2010; 21: 749-58.
22. Köhne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, Braumann D, Joosens E, Müller L, Janssens J, Bokemeyer C, Reimer P, Link H, Späth-Schwalbe E, Wilke HJ, Bleiberg H, Van Den Brande J, Debois M, Bethe U, Van Cutsem E,. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008; 19: 920-6.
23. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J,. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-86.
24. Van Cutsem E, Nordlinger B, Cervantes A,. ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010; 21 Suppl 5:v93-7.
25. Falvella FS, Cheli S, de Braud F, Clementi E, Pietrantonio F,. Predictive testing for DPD deficiency in a patient with familial history of fluoropyrimidine-associated toxicity. Pers Med 2014; 11: 259-62.
26. Gross E, Ullrich T, Seck K, Mueller V, de Wit M, von Schilling C, Meindl A, Schmitt M, Kiechle M,. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat 2003; 22: 498.
27. Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, Harper P, Maisey N, Ross P, Sanderson JD, Marinaki AM,. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer 2013; 108: 2505-15.
28. Amstutz U, Farese S, Aebi S, Largiadèr CR,. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics 2009; 10: 931-44.
29. Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB,. HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) to predict toxicity in stage III colon cancer (CC) patients (pts) (NCCTG Alliance N0147). J Clin Oncol 2015; 33: (suppl 3; abstract 508).